The Central Laboratory of Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, Jiangsu Province, China.
BMC Med Genet. 2011 Jul 12;12:94. doi: 10.1186/1471-2350-12-94.
Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in the ADIPOQ and its type 1 receptor (ADIPOR1) could affect the risk of CRC.
We measured five polymorphisms in the ADIPOQ and two polymorphisms in ADIPOR1, and analyzed their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.
Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95% confidence interval) associated with the ADIPOR1 genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59 (95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI, 1.03-2.05).
We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) in ADIPOR1 are the protective factors for CRC, while that rs266729G/C and G allele of ADIPOQ are the risk factors for colon cancer after excluding rectal cancer cases.
脂联素(ADIPOQ)表达降低与人类结直肠癌(CRC)的发病风险增加有关。本研究旨在确定 ADIPOQ 及其 1 型受体(ADIPOR1)中的多态性是否会影响 CRC 的风险。
我们测量了 ADIPOQ 中的 5 个多态性和 ADIPOR1 中的 2 个多态性,并分析了它们与 420 例 CRC 患者和 555 名年龄和性别匹配的健康个体的 CRC 风险之间的关联。
多变量逻辑回归分析显示,ADIPOR1 基因型与 CRC 风险(调整后的优势比和 95%置信区间)相关的结果为 rs12733285C/T 的 0.53(95%CI,0.35-0.81),rs1342387A/G 的 0.59(95%CI,0.45-0.78),以及 rs1342387A/A 的 0.59(95%CI,0.39-0.89)。此外,在 rs1342387A/G 的等位基因 A 携带者中,风险更为显著(调整后的 OR,0.59;95%CI,0.46-0.77),而非携带者(G/G)。在进一步的亚组分析中,我们观察到 rs266729G/C 与结肠癌(调整后的 OR,1.50;95%CI,1.05-2.14)的发病风险增加相关,但与直肠癌(调整后的 OR,0.88;95%CI,0.63-1.22)无关,并且 G 等位基因携带者患结肠癌的风险增加(调整后的 OR,1.45;95%CI,1.03-2.05)。
我们的结论是,ADIPOR1 中的 rs12733285C/T 基因型和 rs1342387 的 A 等位基因(A/G 或 A/A)携带是 CRC 的保护因素,而 ADIPOQ 的 rs266729G/C 和 G 等位基因是排除直肠癌病例后结肠癌的风险因素。